IV BAL101553: Additional Phase I/IIa data

Data from 39 evaluable patients who failed standard therapy in an open-label, U.K.

Read the full 136 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE